Prevention of type 2 diabetes: An update

Current Diabetes Reports

Volumn 7, Issue 3, 2007, Pages 200-207

  Farag, Amal ^a   Karam, Jocelyne ^b   Nicasio, John ^b   McFarlane, Samy I ^b  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE; CAPTOPRIL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FATTY ACID; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; LOSARTAN; METFORMIN; NATEGLINIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLACEBO; PRAVASTATIN; RAMIPRIL; RIMONABANT; ROSIGLITAZONE; TETRAHYDROLIPSTATIN; TROGLITAZONE; UNINDEXED DRUG; VALSARTAN;

AGE; BARIATRIC SURGERY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIET RESTRICTION; DIET THERAPY; DISEASE CONTROL; DRUG MECHANISM; EPIDEMIC; EXERCISE; GLUCOSE BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; HYPERTENSION; IMMOBILIZATION; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; LIFESTYLE MODIFICATION; LIVER TOXICITY; MEDICAL RESEARCH; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREVALENCE; PROPHYLAXIS; REVIEW; RISK FACTOR; STOMACH SURGERY; WEIGHT REDUCTION;

DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LIFE STYLE; MALE; PREDIABETIC STATE; WEIGHT LOSS;

EID: 34250785741     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-007-0032-4     Document Type: Review

References (60)

1. World Health Organization: Diabetes (Fact Sheet No 312; September 2006). Available at http://www.who.int/media-centre/factsheets/fs3l2/ en/. Accessed December 22, 2006.
2. National Center for Health Statistics, Centers for Disease Control and Prevention: 1999-2003 National Health Interview Survey (NHIS), National Diabetes Fact Sheet 2005. Available at http://www.cdc.gov/ nchs/nhis.htm. Accessed December 22, 2006.
3. Wild S, Roglic G, Green A, et al.: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053.
4. McFarlane SI, Shin J, Rundek T, et al.: Prevention of type 2 diabetes. Curr Diab Rep 2003, 3:235-241.
5. Dormandy J, Charbonnel B, Eckland D, et al.: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitazone Clinical Trial in macrovascular Events): a randomized controlled trial. Lancet 2005, 366:1279-1289.
6. McFarlane SI, Jacober SJ, Winer N, et al.: Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care 2002, 25:718-723.
7. McFarlane SI, Sowers JR: Gender disparities in the control of cardiovascular risk factors in people with diabetes. J Clin Hypertens (Greenwich) 2005, 7:383-385.
8. Saydah SH, Fradkin J, Cowie CC: Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004, 291:335-342.
9. Department of Health and Human Services, Centers for Disease Control and Prevention: Preventing Diabetes and Its Complications. Available at http://www.cdc.gov/nccdphp/publications/factsheets/Prevention/ diabetes.htm. Accessed December 22, 2006.
10. American Diabetes Association: Economic costs of diabetes in the U.S. in 2002. Diabetes Care 2003, 26:917-932.
11. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis of Diagnostic criteria in Europe [no authors listed]. Lancet 1999, 354:617-621.
12. Hu FB, Stampfer MJ, Haffner SM, et al.: Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 2002, 25:1129-1134.
13. Califf RM: Insulin resistance: a global epidemic in need of effective therapies. Eur Heart J Suppl 2003, 5(suppl C]: C13-C18.
14. Mokdad AH, Ford ES, Bowman BA, et al.: Prevalence of obesity, diabetes, and obesity-related health risk factors 2001. JAMA 2003, 289:76-79.
15. Sowers JR, Epstein M, Frolich ED: Diabetes, hypertension and cardiovascular disease: an update. Hypertension 2001, 37:1053-1059.
16. Hussain A, Claussen B, Ramachandran A, et al.: Prevention of type 2 diabetes: a review. Diabetes Res Clin Pract 2006, Oct 25; [Epub ahead of print].
17. Tuomilehto J, Lindstrom J, Eriksson JG, et al.: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001, 344:1343-1350.
18. Knowler WC, Barrett-Connor E, Fowler SE, et al.: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N EnglJ Med 2002, 346:393-403.
19. Eriksson KF, Lindgarde F: Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmo feasibility study. Diabetologia 1991, 34:891-898.
20. Pan XR, Li GW, Hu YH, et al.: Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997, 20:537-544.
21. Long SD, O'Brien K, MacDonald KG Jr, et al.: Weight loss in severely obese subjects prevents the prevention of impaired glucose tolerance test to type II diabetes. A longitudinal interventional study. Diabetes care 1994, 17:372-375.
22. Devlin JT: Effects of exercise on insulin sensitivity in humans. Diabetes Care 1992, 15:1690-1693.
23. Kirpichnikov D, McFarlane SI, Sowers J: Metformin: an update. Ann Intern Med 2002, 137:25-33.
24. Zinman B, Harris SB, Gerstein HC, et al.: Preventing type 2 diabetes using combination therapy: design and methods of the Canadian Normoglycaemia Outcomes Evaluation (CANOE) trial. Diabetes Obes Metab 2006, 8:531-537.
25. El Atat F, Nicasio J, Clarke L, et al.: Beneficial cardiovascular effects of thiazolidinediones. Therapy 2005, 2:113-119.
26. Buchanon A, Xiang A, Peters R, et al.: Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002, 51:2796-2803.
27. DREAM Trial Investigators: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 2006, 368:1096-1105.
28. ClinicalTrials.gov: Actos Now for Prevention of Diabetes (ACT NOW). Available at http://www.clinicaltrials.gov/ct/show/ NCT00220961?order=1. Accessed December 27,2006.
29. Chiasson JL, Josse RG, Leiter LA, et al.: The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Diabetes Care 1996, 19:1191-1194.
30. Chiasson JL, Josse RG, Gomis R, et al.: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002, 359:2072-2077.
31. Van de Laar FA, Lucassen PL, Akkermans RP, et al.: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose. Cochrane Database Syst Rev 2006, 4:CD005061.
32. Sato Y, Nishikawa. M, Shinkai H, Sukegawa E.: Possibility of ideal blood glucose control by a new oral hypoglycemic agent, N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanine (A-4166), and its stimulatory effect on insulin secretion in animals. Diabetes Res Clin Prac 1991, 12:53-59.
33. The NAVIGATOR Trial Steering Committee: Nateglinide and Valsartan in impaired glucose tolerance outcomes research, rationale and design of the Navigator Trial [abstract]. Diabetes 2002, 51(suppl 2):A116.
34. Yusuf S, Gerstein H, Hoogwerf B, et al.: Ramipril and the development of diabetes. JAMA 2001, 286:1882-1885.
35. Hansson L, Lindholm LH, Niskanen L, et al.: Effect of angiotensin-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial. Lancet 1999, 353:611-616.
36. ALLHAT Officers and coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981-2997.
37. Dahlof B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:1004-1010.
38. Gillespie EL, White CM, Kardas M, et al.: The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care 2005, 28:2261-2266.
39. DREAM Trial Investigators: Effect of ramipril on the incidence of diabetes. N Engl J Med 2006, 355:1551-1561.
40. Teo K, Yusuf S, Sleight P, et al.: Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCED) trials. Am Heart J 2004, 148:52-61.
41. McFarlane SI, Kumar A, Sowers JR: Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol 2003, 91:H30-H37
42. Henriken EJ, Jacob S: Modulation of metabolic control by angiotensin converting enzyme (ACE) inhibition. J Cell Physiol 2003, 196:171-179.
43. Carlsson PO, Berne C, Jansson L: Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia 1998, 41:127-133.
44. Scheen A: Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system. Drugs 2004, 64:2537-2565.
45. Heymsfield SB, Segal KR, Hauptman J, et al.: Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 2000, 160:1321-1326.
46. Torgerson JS, Hauptman J, Boldrin MN, et al.: Xenical in the prevention of diabetes in obese subjects (XENDOS) Study. Diabetes Care 2004, 27:155-161.
47. Despres JP, Golay A, Sjostrom L, et al.: Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005, 353:2121-2134.
48. Van Gaal LF, Rissanen AM, Scheen AJ, et al.: Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005, 365:1389-1397.
49. Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al.: Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. JAMA 2006, 295:761-775.
50. Scheen AJ, Finer N, Hollander P, et al.: Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes. Lancet 2006, 368:1160-1172.
51. McFarlane SI, Muniyappa R, Francisco R, et al.: Clinical review 145: Pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab 2002, 87:1451-1458.
52. Freeman DJ, Norrie J, Sattar N, et al.: Pravastatin and the Development of diabetes mellitus: evidence of a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001, 103:357-362.
53. Tenenbaum A, Motto M, Fisman EZ: Dual and panperoxisome proliferator receptor (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc Diabetol 2005, 4:14.
54. Rovellini A, Sommariva D, Branchi A, et al.: Effects of slow release bezafibrate on the lipid pattern and on blood glucose of type 2 diabetic patients with hyperlipidaemia. Pharmacol Res 1992, 25:237-245.
55. Tenenbaum A, Motto M, Fisman EZ, et al.: Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients. Eur Heart J 2005, 26:2032-2038.
56. Tenenbaum A, Motro M, Fisman E, et al.: Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation 2004, 109:2197-2202.
57. Sjostrom L, Lindroos AK, Peltonen M, et al.: Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Eng J Med 2004, 351:2683-2693.
58. Sjostrom CD: Surgery as an intervention for obesity. Results from the Swedish Obese Subjects Study. Growth Horm IGF Res 2003, 13:S22-S26.
59. Pories WJ, Swanson MS, MacDonald KG, et al.: Who would have thought it? An operation proves to be the most effective therapy for adult onset diabetes mellitus. Ann Surg 1995, 222:339-350.
60. Long SD, O'Brien K, MacDonald KG Jr, et al.: Weight loss in severely obese subjects prevents the prevention of impaired glucose tolerance test to type II diabetes. A longitudinal interventional study. Diabetes Care 1994, 17:372-375.